ALBUQUERQUE, NEW MEXICO – The State of New Mexico has reached a $2.25 million settlement with pharmaceutical company Mylan Inc. over allegations tied to the pricing of EpiPen Auto‑Injector products, which are used to treat severe allergic reactions.
Attorney General Raúl Torrez announced the settlement this week, saying the state alleged Mylan’s pricing and business practices violated New Mexico consumer protection and antitrust laws. According to the New Mexico Department of Justice, those practices included delaying the introduction of lower‑cost generic versions, pursuing patent litigation strategies, marketing decisions, and setting product prices.
Mylan denied any wrongdoing or liability related to the allegations but agreed to the settlement terms. As part of the agreement, the company will pay $2.25 million to the State of New Mexico. Officials say the funds will be used to help cover investigation costs, programs, personnel, training, and urgent health care needs.
In addition to the monetary payment, the settlement requires Mylan to increase its co‑pay coupon for its authorized generic EpiPen in New Mexico. The company will also donate up to 10,000 EpiPen devices to the state for distribution and work with state officials to increase awareness of the EpiPen4Schools Program, which provides EpiPens to schools at no cost.
“This settlement serves as an important protection for New Mexico consumers and families who depend on affordable access to life‑saving epinephrine products,” Attorney General Torrez said in a statement.
State officials say the settlement resolves the claims without requiring Mylan to admit liability.
